Mblast Tablet contains a combination of Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions. Levocetirizine is a selective, non-sedating antihistamine that competitively inhibits peripheral histamine H1-receptors, thereby reducing symptoms such as sneezing, nasal discharge, itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, making it effective in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The combination of these agents provides a dual mechanism of action, targeting both histaminergic and leukotriene pathways, resulting in improved symptom control in patients with allergic rhinitis, asthma, and related hypersensitivity disorders. Mblast Tablet is indicated for patients requiring both antihistaminic and leukotriene receptor antagonist therapy to achieve optimal relief from allergic symptoms. It is generally well tolerated, with adverse effects including headache, fatigue, and gastrointestinal disturbances being uncommon. Use of Mblast should be under medical supervision, especially in patients with hepatic or renal impairment, and it is contraindicated in individuals with known hypersensitivity to any component of the formulation.